All stock lists
Erasca, Inc. (NASDAQ:ERAS)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
15.48-0.13 (-0.83%)
Market cap
$5.41B
Insider Score
Health Score
Analyst consensus
Listed since
Jul 16, 2021
Website
Insider Score
––Not scored
ERAS Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
ERAS analyst forecast
ERAS analyst consensus
Moderate Buy3 ratings
Buy 2 Hold 1 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
ERAS 12-month price target
No published price targets in the last 12 months.
ERAS ratings mix, last 12 months
Buy Hold Sell
Best analysts covering ERAS
- HC Wainwright & Co.33%success rate · +152.7% avg return · 9 calls
- Mizuho33%success rate · +6.9% avg return · 3 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
ERAS analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | B of A Securities | Neutral | — | — | Reiterated | 2026-08-14 |
| — | Guggenheim | Buy | — | — | Reiterated | 2026-08-13 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-08-12 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2026-07-20 |
| — | B of A Securities | Neutral | — | — | Reiterated | 2026-07-14 |
| — | B of A Securities | Neutral | — | — | Upgraded | 2026-06-04 |
| — | Mizuho | Outperform | — | — | Reiterated | 2026-05-12 |
| — | Stifel | Buy | — | — | Reiterated | 2026-04-27 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2026-03-18 |
| — | Guggenheim | Buy | — | — | Reiterated | 2026-03-16 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2026-03-13 |
| — | Mizuho | Outperform | — | — | Reiterated | 2026-03-13 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-03-13 |
| — | Clear Street | Buy | — | — | Reiterated | 2026-03-06 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-01-26 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2026-01-16 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-01-13 |
| — | Mizuho | Outperform | — | — | Reiterated | 2025-12-09 |
| — | Guggenheim | Buy | — | — | Reiterated | 2025-11-14 |
| — | B of A Securities | Underperform | — | — | Downgraded | 2025-09-03 |
| — | Morgan Stanley | Equal Weight | — | — | Downgraded | 2025-08-18 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-04-30 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-03-21 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2025-03-21 |
| — | B of A Securities | Buy | — | — | Upgraded | 2025-01-07 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-11-13 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-10-25 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2024-10-25 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2024-08-14 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-08-13 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2024-05-28 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-05-20 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-05-09 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2024-04-02 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-03-28 |
| — | B of A Securities | Neutral | — | — | Downgraded | 2024-01-05 |
| — | Mizuho | Buy | — | — | Reiterated | 2023-11-29 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-11-28 |
| — | Evercore ISI Group | Outperform | — | — | Reiterated | 2023-06-06 |
| — | Mizuho | Buy | — | — | Reiterated | 2023-06-06 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2023-05-16 |
| — | Mizuho | Buy | — | — | Reiterated | 2023-03-30 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2023-02-24 |
| — | Morgan Stanley | Overweight | — | — | Upgraded | 2023-02-03 |
| — | Guggenheim | Buy | — | — | Reiterated | 2021-08-10 |
| — | B of A Securities | Buy | — | — | Reiterated | 2021-08-10 |
| — | Evercore ISI Group | Outperform | — | — | Reiterated | 2021-08-10 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2021-08-10 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2021-08-10 |
ERAS earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-03-12 | -0.11 | -0.10 | $0 | $0 |
| 2026-05-11 | -0.11 | -0.60 | $0 | $0 |
| 2026-08-12 | -0.11 | -0.14 | $0 | $0 |
| 2026-11-11 | -0.13 | 0.00 | $0 | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.